Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of recombinant human erythropoietin-HyFc fusion protein injection for renal anemia in dialysis patients with chronic kidney disease
CTR20210135Phase 2Active
- Sponsor
- Shanghai Kaimao Biopharmaceutical
- Start
- Jan 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efepoetin alfa in Uraemic Anaemia, sponsored by Shanghai Kaimao Biopharmaceutical. Started Jan 2021; status: active.
02
Drugs
efepoetin alfa
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on CTR20210135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210135.